SITC 2021: Preclinical data for SNS-101
Antagonistic pH-selective VISTA antibody SNS-101 potentiates anti-PD-1/PD-L1-induced anti-tumor immunity. See PDF here.
ASCO 2021: Safety and Efficacy Update
Early Safety and Efficacy of a Phase 1/2 Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients with ASPH+Locally Advanced Unresectable or Metastatic/Recurrent Squamous Cell Carcinoma of the Head and Neck. See PDF here.
SITC Safety and Efficacy
Early Safety and Efficacy of a Phase 1/2 Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients with ASPH+Locally Advanced Unresectable or Metastatic/Recurrent Squamous Cell Carcinoma of the Head and Neck. See PDF here.
Refractory Head and Neck Cancer Enrollment Update
Early Safety and Efficacy of a Phase 1/2 Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients with Advanced SquamousCell Carcinoma of the Head and Neck. See PDF here.
SITC TIP
Phase 1/2 Open-Label, Multi-Center Trial of SNS-301 Added to Pembrolizumab in Patients with Advanced Squamous Cell Carcinoma of the Head & Neck. See PDF here.